scholarly journals A US hospital budget impact analysis of a skin closure system compared with standard of care in hip and knee arthroplasty

2018 ◽  
Vol Volume 11 ◽  
pp. 1-11 ◽  
Author(s):  
Kay Sadik ◽  
Jana Flener ◽  
Jeanine Gargiulo ◽  
Zachary Post ◽  
Steven Wurzelbacher ◽  
...  
Keyword(s):  
Knee Arthroplasty ◽  
Impact Analysis ◽  
Budget Impact ◽  
Standard Of Care ◽  
Budget Impact Analysis ◽  
Skin Closure ◽  
Closure System ◽  
Hospital Budget ◽  
Hip And Knee Arthroplasty

scholarly journals Use of Oritavancin for the Treatment of Skin and soft Tissue Infections: A Uk Hospital Budget Impact Analysis

2015 ◽  
Vol 18 (3) ◽  
pp. A233 ◽  
Author(s):  
C. Wu ◽  
I.S. Jensen ◽  
P.L. Cyr ◽  
W. Fan ◽  
M. Mitchell ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Soft Tissue Infections ◽  
Hospital Budget

PP39 Budget Projections And Health Impact Of PD-1/PD-L1 Inhibitors

2019 ◽  
Vol 35 (S1) ◽  
pp. 44-45
Author(s):  
Alexander Roediger ◽  
Julie van Bavel ◽  
James Pellissier ◽  
Stefano Lucherini ◽  
Neil Davies ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Treatment Options ◽  
Model Development ◽  
Standard Of Care ◽  
Health Impact ◽  
Budget Impact Analysis ◽  
Rapid Expansion ◽  
Projection Model ◽  
Life Years

IntroductionThe rapid expansion of immuno-oncology treatment options has led to concerns around their long-term affordability. Evidence on the potential budget and health impact of these new treatment options is required to inform public health policy and ensure adequate allocation of budget for the future.MethodsThe Health Impact Projection model was developed to compare the economic impact and health outcomes observed with and without PD-1/PD-L1 inhibitors using traditional budget impact analysis. Seven types of high-incidence cancers were included: melanoma, first- and second-level non-small cell lung, bladder, head and neck, renal cell carcinoma, and triple negative breast. Inputs were based on publicly available data and literature, and over 10 key experts (oncologists, health economists) were involved in the model development. The model draws on five-year budget impact analysis.ResultsUsing the experience of Belgium, Slovenia, Switzerland, and Italy, the model estimates budget and health impact of the PD-1/PD-L1 inhibitor class. It shows that for 2018-2022, the class will provide additional life years and avoid high-grade adverse events (AEs) with a manageable budget impact per year compared to the standard of care. The model also enables policy-makers to assess the adequacy of their budget for the near future and explore the implications of different policy decisions. Results for Belgium show that over the five-year period the PD-1/PD-L1 inhibitors will save 10,635 additional life years, avoid 7,597 AEs and have a budget impact of approximately EUR 260 million. Results for Slovenia show 1,468 additional life years gained and 869 AEs avoided with a budget impact of approximately EUR 116 million; for Switzerland, 6,775 life years gained, 6,953 AEs avoided, and EUR 106 million budget impact; and for Italy, 5,019 life years gained, 2,040 AEs avoided, and EUR 627 million budget impact.ConclusionsAlthough limitations exist, the model informs planning by helping quantify the potential impact of immune-oncology treatments on health and budget in different scenarios.

scholarly journals A device category economic model of electrosurgery technologies across procedure types: a U.S. hospital budget impact analysis

2021 ◽  
Vol 24 (1) ◽  
pp. 524-535
Author(s):  
Nicole Ferko ◽  
George W. J. Wright ◽  
Imran Syed ◽  
Elena Naoumtchik ◽  
Giovanni A. Tommaselli ◽  
...  
Keyword(s):  
Economic Model ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Hospital Budget

scholarly journals A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Florian Jakobs ◽  
Sebastian Marcel Wingen-Heimann ◽  
Julia Jeck ◽  
Anna Kron ◽  
Oliver Andreas Cornely ◽  
...  
Keyword(s):  
High Risk ◽  
Length Of Stay ◽  
Impact Analysis ◽  
Budget Impact ◽  
Hospital Management ◽  
Standard Of Care ◽  
Budget Impact Analysis ◽  
Hospital Length Of Stay ◽  
Potential Cost ◽  
Management Perspective

Abstract Background Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1 A guideline recommendation for prevention of CDI, after randomized clinical trials demonstrated its superior efficacy vs. placebo. Methods The budget impact analysis at hand is focused on patients at high risk of CDI recurrence. Treatment with standard of care (SoC) + bezlotoxumab was compared with current SoC alone in the 10 most associated Diagnosis Related Groups to identify, analyze, and evaluate potential cost savings per case from the German hospital management perspective. Based on variation in days to rehospitalization, three different case consolidation scenarios were assessed: no case consolidation, case consolidation for the SoC + bezlotoxumab treatment arm only, and case consolidation for both treatment arms. Results On average, the budget impact amounted to € 508.56 [range: € 424.85 - € 642.19] for no case consolidation, € 470.50 [range: € 378.75 - € 601.77] for case consolidation in the SoC + bezlotoxumab treatment arm, and € 618.00 [range: € 557.40 - € 758.41] for case consolidation in both treatment arms. Conclusions The study demonstrated administration of SoC + bezlotoxumab in patients at high risk of CDI recurrence is cost-saving from a hospital management perspective. Reduced length of stay in bezlotoxumab treated patients creates free spatial and personnel capacities for the treating hospital. Yet, a requirement for hospitals to administer bezlotoxumab is the previously made request for additional fees and a successful price negotiation.

Sign in / Sign up

Export Citation Format

Share Document